Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy.
Takeuchi T, Fleischmann R, Iikuni N, Shi H, Soma K, Paulissen J, Hirose T, Smolen JS. Takeuchi T, et al. Among authors: shi h. Arthritis Res Ther. 2021 Aug 24;23(1):220. doi: 10.1186/s13075-021-02591-y. Arthritis Res Ther. 2021. PMID: 34429160 Free PMC article. Clinical Trial.
Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift).
Cohen SB, Pope J, Haraoui B, Mysler E, Diehl A, Lukic T, Liu S, Stockert L, Germino R, Menon S, Shi H, Keystone EC. Cohen SB, et al. Among authors: shi h. RMD Open. 2021 Jun;7(2):e001673. doi: 10.1136/rmdopen-2021-001673. RMD Open. 2021. PMID: 34103405 Free PMC article. Clinical Trial.
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.
Winthrop KL, Citera G, Gold D, Henrohn D, Connell CA, Shapiro AB, Shi H, Onofrei AM, Pappas DA, Schulze-Koops H. Winthrop KL, et al. Among authors: shi h. Ann Rheum Dis. 2021 Jan;80(1):134-136. doi: 10.1136/annrheumdis-2020-218992. Epub 2020 Oct 12. Ann Rheum Dis. 2021. PMID: 33046447 Free PMC article. No abstract available.
Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).
Rosenstock J, Frias J, Páll D, Charbonnel B, Pascu R, Saur D, Darekar A, Huyck S, Shi H, Lauring B, Terra SG. Rosenstock J, et al. Among authors: shi h. Diabetes Obes Metab. 2018 Mar;20(3):520-529. doi: 10.1111/dom.13103. Epub 2017 Oct 2. Diabetes Obes Metab. 2018. PMID: 28857451 Clinical Trial.
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
Dagogo-Jack S, Frederich R, Liu J, Cannon CP, Shi H, Cherney DZI, Cosentino F, Masiukiewicz U, Gantz I, Pratley RE. Dagogo-Jack S, et al. Among authors: shi h. J Clin Endocrinol Metab. 2023 Jul 14;108(8):2042-2051. doi: 10.1210/clinem/dgac764. J Clin Endocrinol Metab. 2023. PMID: 36702781 Free PMC article. Clinical Trial.
15,224 results
You have reached the last available page of results. Please see the User Guide for more information.